Gynecologic malignancies—particularly ovarian, endometrial, and cervical cancers—remain major contributors to cancer morbidity and mortality, driven by late diagnosis, high relapse rates, and therapy resistance. Over the past…
PARP Inhibitors Combined With Immune Checkpoint Blockade in Gynecologic Cancers
